Basal Insulin 4.0: Updating Your Clinical Practice with Ultralong-Acting Insulins and Insulin Combination Therapy
Current treatment guidelines recognize the progressive natural history of type 2 diabetes mellitus (T2DM) and the eventual need to add antihyperglycemic agents to the treatment regimen as β-cell function is lost. To maintain glycemic control, most patients with T2DM will eventually require exogenous insulin therapy, often in combination with noninsulin agents. Accordingly, endocrinologists need to be familiar with the therapeutic characteristics of a variety of insulin-based treatment regimens for T2DM as they are the experts from whom other clinicians request advice on diabetes management (especially insulin therapy). This continuing medical education (CME) activity is designed to provide practical guidance on new ultralong-acting basal insulin analogues and how to use prandial insulin with these analogues and to review clinical outcomes associated with using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to intensify long- or ultralong-acting basal insulin analogue therapy.
Method of Physician Participation/How to Obtain CME Credit
- It is anticipated that this activity will take 1.75 hours to complete.
- Read the educational material.
- Complete the posttest questions and get a passing mark of 70% or higher.
- Complete the CME Activity Evaluation form.
- Fax/mail/email the completed posttest and evaluation form for processing to:
25 Independence Boulevard,
Suite 402, Warren, NJ 07059
- Only those who get a score of 70% or higher will receive credit.
- Allow 4-6 weeks for processing of CME certificates.
This activity is intended for endocrinologists and other endocrinology healthcare providers who treat patients with T2DM.
At the conclusion of this activity, participants should be able to:
- Compare long-and ultralong-acting basal insulin analogues regarding their pharmacokinetics, efficacy, variability, and hypoglycemia and weight effects
- Explain how to use prandial insulin with ultralong-acting basal insulin analogues
- Review clinical outcomes associated with using a GLP-1 RA to intensify longor ultralong-acting basal insulin therapy.
Alan J. Garber, MD, PhD, FACE; Bruce Bode, MD, FACE; Guillermo E. Umpierrez, MD, FACP, FACE, CDE; Luigi F. Meneghini, MD, MBA
- 1.75 AMA
- 1.75 Attendance